A detailed history of Fifth Third Bancorp transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Fifth Third Bancorp holds 1,000 shares of BPMC stock, worth $90,460. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,000
Previous 1,000 -0.0%
Holding current value
$90,460
Previous $107,000 14.02%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 19, 2022

SELL
$54.1 - $110.08 $3,841 - $7,815
-71 Reduced 6.63%
1,000 $64,000
Q4 2021

Feb 01, 2022

SELL
$94.25 - $115.99 $6,409 - $7,887
-68 Reduced 5.97%
1,071 $115,000
Q3 2021

Oct 15, 2021

SELL
$80.98 - $109.47 $4,291 - $5,801
-53 Reduced 4.45%
1,139 $117,000
Q2 2021

Aug 06, 2021

SELL
$82.78 - $101.0 $7,532 - $9,191
-91 Reduced 7.09%
1,192 $105,000
Q1 2021

May 07, 2021

SELL
$90.71 - $108.28 $14,604 - $17,433
-161 Reduced 11.15%
1,283 $125,000
Q4 2020

Feb 16, 2021

SELL
$92.08 - $124.48 $245,024 - $331,241
-2,661 Reduced 64.82%
1,444 $162,000
Q3 2020

Nov 09, 2020

SELL
$66.45 - $92.7 $45,518 - $63,499
-685 Reduced 14.3%
4,105 $381,000
Q2 2020

Aug 05, 2020

BUY
$57.09 - $79.27 $273,461 - $379,703
4,790 New
4,790 $374,000
Q4 2018

Feb 14, 2019

SELL
$45.57 - $74.26 $3,736 - $6,089
-82 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$58.91 - $78.32 $4,182 - $5,560
-71 Reduced 46.41%
82 $6,000
Q4 2017

Feb 14, 2018

SELL
$62.91 - $88.32 $32,901 - $46,191
-523 Reduced 77.37%
153 $12,000
Q3 2017

Nov 14, 2017

BUY
$42.37 - $69.67 $28,642 - $47,096
676
676 $47,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.